throbber
The EMBO Journal vol.6 no.3 pp.605-610. 1987
`~verexpression of the EGF receptor-related proto-oncogene erbB-2
`m human mammary tumor cell lines by different molecular
`mechanisms
`
`Motthios ff .Kraus, Nicholas C.Popcscu 1, Suzanne
`C.Amsbaugh1 and C.Richter King
`La~ratory of Cellular and Molecular Biology. and 1Laboratory of Biology.
`Nauonal Cancer Institute. Building 37. Room IE24, Bethesda, MD 20892,
`USA
`Communicated by J.Schlessinger
`Amplification of the erbB/EGF receptor and a structurally
`related gene, designated erbB-2, have previously been detected
`in a variety of human tumors. In a series of human mam(cid:173)
`mary tumor cell lines, analysis of transcripts of these genes
`revealed elevated levels of one or the other in more than 60%
`of tumors analyzed. Eight cell lines demonstrated erbB-2
`mRNA levels ranging from 4- to 128-fold above those of nor(cid:173)
`mal controls. erbB-2 expression was evaluated in comparison
`to the expression level of actin observed in these cell lines.
`There was no evidence of an aberrantly sized erbB-2
`transcript in any of these lines. lmmunoblot analysis indicated
`elevation in levels of the 185-kd product of the erbB-2 gene
`exp~ by these cells. In four lines erbB-2 gene amplifica(cid:173)
`tion in the absence of an apparent gene rearrangement was
`demonstrated. In a repr esentative cell line of this type, SK(cid:173)
`BR-3, the amplified erbB-2 gene copies were located in an
`at>t:rrant chromosomal location. Four additional cell lines,
`which demonstrated 4- to 8-fold overexpression of erbB-2
`mRNA, did not exhibit gene amplification. In a representative
`cell line of this type ZR-75-1, an apparently normal chromo(cid:173)
`somal location was found for the erbB-2 gene. Our findings
`indicate that overexpr~ion of the erbB-2 gene in mammary
`tumor cell lines is frequent and associated with different
`genetic abnormalities.
`Key words: erbB-2/gene amplification/growth factor receptor/
`marrunary neoplasia/ overexpression
`
`Introduction
`Cellular genes encoding effector molecules of growth regulation
`have been linked to the neoplastic process based on their
`homology to retroviral oncogenes. The c-sis proto-oncogene en(cid:173)
`codes a chain of platelet-derived growth factor (POOF) (Doo(cid:173)
`little et al., 1983; Waterfield et al., 1983), the v-erbB oncogene
`has been shown to encode a truncated form of the epidermal
`growth factor (EGF) receptor (Downward et al. , 1984), and the
`c-fms proto-oncogene product is related to the receptor for mono(cid:173)
`nuclear phagocyte growth factor (CSF-IR) (Sherr et al . • 1985).
`More recently, we and others (King et al., 1985a; Schechter et
`al., 1985; Semba et al., 1985; Coussens et al. , 1985) have iden(cid:173)
`tified a second cellular analogue of v-erbB in the human genome.
`This gene, designated erbB-2, is related to but distinct from the
`gene encoding the erbBIEGF receptor (EGFR). The predicted
`amino acid sequence of the erbB-2 gene reveals the structural
`features of a growth factor receptor molecule with close similarity
`to the EGF receptor (Coussens et al., 1985; Yamamoto et al.,
`1986a), including a cysteine-rich extracellular domain, transmem-
`
`brane region and a highly conserved tyrosine kinase domain .
`Gene alterations affecting EGFR and erbB-2 occur in tumor
`cells. A dominant cellular transforming gene activated by point
`mutation in chemically induced rat neuroblastomas (Shih et al.,
`1981), neu, is likely to be the rat homologue of human erbB-2
`based on comparative nucleotide sequence analysis and chromo(cid:173)
`somal localization (Schechter et al., 1985; Coussens et al., 1985;
`Yamamoto et al., 1986a; Bargmann et al., 1986a). In human
`glioblastoma, amplification and rearrangement of the EGFR gene
`result in extensive expression of abnormal as well as normal(cid:173)
`s.ized ~As (Libermann et al., 1985). In addition, amplifica(cid:173)
`tion without rearrangements affecting EGFR mRNA size is fre(cid:173)
`quently found in cells derived from squamous cell carcinomas
`(Yamamoto et al., 1986b) and in two distinct manunary car(cid:173)
`cinoma cell lines (King et al., 1985b; Filmus et al., 1985).
`Gene amplification of erbB-2 has been identified in a primary
`mammary adenocarcinoma (King et al., 1985a), as well as in
`a salivary gland adenocarcinoma (Semba et al., 1985). These
`~ndings have s~ggested the possibility that erbB-2 overexpres(cid:173)
`s1on may contribute to neoplastic growth (King et al. , l 985a;
`Semba et al., 1985).
`For this study, we investigated the expression of erbB-2 and
`EGFR in 16 human mammary tumor cell lines. Our results in(cid:173)
`dicate frequent overexpression of these proto-oncogenes that are
`related to growth factor receptors. Furthermore, analysis of the
`erbB-2 gene locus in these cell lines demonstrates that enhanced
`erbB-2 expression can occur in the presence or the absence of
`gene amplification, suggesting that different molecular mechan(cid:173)
`isms result in overexpression of normal size erbB-2 mRNA in
`mammary tumor cells.
`
`Results
`Isolation of erbB-2 complementary DNA
`To allow a comprehensive analysis of erbB-2 mRNA and gene
`structure we isolated cDNAs with a complexity of over 4.5 kb
`from the mRNA (Figure IA). An oligo (dT) primed normal
`human fibroblast cDNA library (Okayama and Berg, 1983) was
`screened with a 0.8 kbp Accl DNA fragment from a genomic
`clone of erbB-2 (King et al., 1985a). The largest plasmid ob(cid:173)
`tained, pMAC137, carried a 2-kbp insert comprising 1.5 kbp of
`3' coding information and 3' untranslated sequence. 11le remain(cid:173)
`ing coding information upstream was obtained from three phage
`clones, >..MAC30, AMACIO' and >..MAC14-l , identified in a ran(cid:173)
`domly primed MCF-7 cDNA library (Walter et al., 1985; Figure
`IA). Nucleotide sequence analysis and restriction mapping of
`the entire cDNA indicated that its structure was the same as an
`isolate from normal human placenta (Coussens et al., 1985).
`Overexpression of erbB-2 or EGFR proto-oncogenes in human
`mammary tumor cell lines
`To assess the role of erbB-2 in human marrunary neoplasia we
`compared the mRNA of 16 mammary tumor cell lines to nor(cid:173)
`mal human fibroblasts , M413, and a human marrunary epithelial
`cell line, HBLlOO. Increased expression of an apparently nor-
`
`605
`
`1 of 6
`
`Celltrion, Inc., Exhibit 1046
`
`

`

`M.H.Kraus el al.
`
`A
`
`NN
`
`5'
`
`II
`
`St
`
`I
`
`811
`
`811 E
`
`I 11 II
`
`PP Sp8P88
`
`I l 111
`
`8SmEKSm811P
`
`~I~ 11
`
`St
`
`I
`
`3 '
`
`E
`
`E
`
`E
`
`E
`
`pMAC137
`
`>. MAC30
`
`>.MAC10"
`
`>.MAC14-1
`
`2
`
`3
`
`4
`
`5
`
`kbp
`
`0
`
`B
`
`•
`
`Fig. 1. (A) Isolation and restriction mapping of erbB-2 cDNA. Clone pMACl37 was isolated from an oligo (dn primed nom1al human fibroblast cDNA
`library (Okayama and Berg, 1983). Clones >.MAC30, >.MAC 10' and >.MAC14- l were subsequently obtained from a randomly primed MCF-7 cDNA library
`{Walter et al., 1985). Restriction sites: B = BamHI. Bil = BstEll , E = EcoRI. N = Ncol. P = Pstl. Sm = Smal. Sp = Splrl and St = Srul. (8) cDNA
`probes used in hybridization analysis.
`
`c
`
`A
`
`B
`
`>l
`
`28s -
`
`18s -
`
`erbB-2
`
`•
`••• ralallv amount 1 32 4 64 32 1l 4 4 4
`
`1
`
`ac:tln
`
`•
`
`• •
`
`• •
`
`relative amount
`
`1 11• 112 112 V7 11• 112
`
`I vc
`
`I
`
`overupre111on
`of ert>B-2
`
`1 128 8 128 64 64 e 4
`
`13 1
`
`Fig. 2. Overexpression of erbB-2 in human mammary rumor cell lines. (A) Nonhem blot analysis. Total cellular RNA (10 µg) of mammary rumor cell lines.
`nonna.I human fibroblasts M413 and HBLIOO was hybridized with a cDNA probe derived from the 5' end of the erbB-2 coding region {Figure lB, probe a).
`M413 and HBLIOO cells contain erbB-2 specific mRNA detectable after longer autoradiographic exposures. (B) Quantitation of erbB-2 mRNA levels. Serial
`2-fold dilutions of total RNA were applied to nitrocellulose. Replicate filters were hybridized with either a erbB-2 cDNA probe (Figu re 18. probe b) or
`human 13-actin which served as control for RNA amounts present on the nitrocellulose filter. Relative amounts detected with each probe are indicated in
`comparison to the hybridization signals observed in normal human fibroblasts M413.
`606
`
`I
`
`..,
`.., • ... 0
`"'
`iD
`..,
`..,
`"'
`' ... .. g
`.., 0
`~
`i
`~ ~
`'
`... ...
`a: "' •
`"'
`.., m
`; ~ I • < ~ ~ ' • -'
`.... 0
`.... m
`a:
`a:
`::E "' N m :::E
`::E N m :c
`•
`
`I
`
`I
`
`:::E
`
`..,
`"' ...
`.., • iii ..,
`;;;;
`"'
`..,
`m m
`.., g
`i
`... ..,
`...
`...
`"' ....
`::E
`:::E
`:::E
`.., m
`a:
`"'
`... < < <
`'
`I
`' • .J
`;
`a: .... m
`.... 0
`I
`a:
`0
`0
`::E N m :c
`::E "' N m ::E
`:::E
`
`0
`
`I
`
`0
`
`2 of 6
`
`Celltrion, Inc., Exhibit 1046
`
`

`

`Overexpr~ion of the erbB-2 gene in mammary tumor cells
`
`Table I. Overexpression of erbB-2 and EGFR proto-oncogenes in human
`mammary neoplasia
`
`EGFR
`erbB-2
`Overexpression Gene
`Overexpression Gene
`amplification
`ampl ification of mRNA3
`of mRNA•
`
`A
`
`(')
`
`(')
`I
`CI:
`.....
`co
`.,
`I
`:io::
`<
`Cl)
`+ - +
`
`MW x 10- 3
`
`B
`
`(')
`,._
`I
`I
`,._
`CI:
`II)
`I
`CD
`u.
`I u
`I
`~ CI:
`Cl) N ~
`
`M41 3
`HBLIOO
`MCF-7
`SK-BR-3
`BT474
`MDA-MB361
`MDA-MB453
`ZR-75-1
`ZR-75-30
`MDA· MB1 75
`BT483
`BT20
`MDA·MB468
`
`I
`128
`128
`64
`64
`8
`4
`8
`8
`
`I
`4-8
`4-8
`2-4
`2
`
`< I
`1
`<I
`I
`
`< I
`I
`
`<I
`1
`< I
`<l
`<l
`16
`32
`
`1
`4-8
`32
`
`'Overexpression above nonnal fibroblast and HBLIOO.
`
`ma! size 5-kb transcript was detected in 8 of 16 tumor cell Jines,
`when total cellular RNA was subjected to Northern blot analysis.
`Figure 2A shows the results using a cDNA probe comprising
`the coding sequences of the amino-terminal extracellular domain
`of erbB-2 (Figure 18, probe a). These results of overexpression
`of normal-sized mRNA were confirmed by hybridization of po(cid:173)
`ly(A) + selected RNA using several erbB-2-specitic probes com(cid:173)
`prising coding information for the transmembrane and tyrosine
`kinase domains. An aberrantly sized erbB-2 mRNA was not
`detected in any of the cell lines analyzed.
`To quantitate more precisely the amount of erbB-2 transcript
`in eight mammary tumor cell lines which overexpress erbB-2,
`serial 2-fold dilutions of total cellular RNA were subjected to
`dot blot analysis using human (3 actin as a control for the amount
`of RNA applied to the nitrocellulose filters. As shown in Figure
`2B, the highest levels of erbB-2 mRNA, which ranged from 64-
`to 128-fold over that of our controls, were observed in the cell
`lines MDA-MB453, SK-BR-3, MDA-MB361 and BT474. More(cid:173)
`over, erbB-2 mRNA levels were increased 4- to 8-fold in four
`cell lines including BT483, MDA-MB175, ZR-75-30 and
`ZR-75-1 (Table I) .
`To determine if the overexpression of erbB-2 mRNA resulted
`in a steady state increase of its encoded gene product, we
`developed a specific immunoblot assay. Antisera were raised
`against a synthetic peptide whose sequence corresponded to a
`portion of the putative erbB-2 tyrosine kinase domain. As this
`region is partially conserved between the encoded proteins of
`the EGFR and erbB-2 genes, we tested its specificity using A43 l
`and SK-BR-3 cell lines which overexpress EGFR or erbB-2
`mRNA, respectively . As shown in Figure 3A, a specific band
`of - 185 kd was detected in ex.tracts of SK-BR-3 but not in A431
`cells. This band was not detected when the antibody was pre(cid:173)
`incubated with the synthetic peptide corresponding to its antigen.
`The human erbB-2 and rat neu products have been reported to
`be glycoproteins of 185 kd (Akiyama et al. , 1986; Stem et al. ,
`1986).
`To estimate the relative amounts of erbB-2 protein in different
`mammary tumor cell lines, immunoblot analysis was conducted
`using equivalent amounts of total cellular protein. As shown in
`Figure 3B, an intense band of protein was detected in extracts
`of SK-BR-3 and a less intense but readily detectable band in ex(cid:173)
`tracts of ZR-75-1. No erbB-2 protein was detected in extracts
`
`-
`
`- 200
`
`- 97
`
`MWX10 - J
`
`- 200
`
`- 97
`
`Fig. 3. Elevated erbB-2 protein levels in mammary tumor cell lines. 40 µg
`total cellular protein was separated by electrophoresis and transferred to
`nitrocellulose filters. The erbB-2 protein was detected with an antipeplide
`antibody coupled to t2S1 protein A. The specificity of antibody detection was
`determined by pre-incubation of the antibody with excess amounts of peptide
`prior to immunodetection. { +) preincubation with peptide. {-) no peptide.
`In panel B, nonspecific bands a1 110 kd are observed in longer exposures of
`peptide-blocked immunoblots (panel A).
`
`A
`
`B
`
`a: .
`;;; ...
`. c
`., ...
`~
`., ID
`" ~ 0
`
`:>
`
`0
`
`"' .
`...
`"' "' -
`... ..
`.
`..
`:>
`'{:'
`a: ~ :;;
`:> "'
`-- -
`- --.-.
`
`;
`
`23 -
`9 • •
`
`6 6 -
`
`• 3 -
`
`2
`
`•
`
`~a 2
`
`t ,at vf l'!!'IOU 1
`
`1
`
`4
`
`8
`
`4
`
`1
`
`1 2
`
`1
`
`•••••••••
`• • • •
`•
`
`1 1 1 ve amount
`
`• \i• ge"I
`y
`O' !:!B 1
`
`1 1
`
`2 2 2
`
`•
`
`,
`
`1
`
`•
`
`1
`
`•
`
`'I
`
`2
`
`Fag. 4. Gene amplification of erbB-2 in mammary tumor ceU lines. {A)
`Southern blot analysis. For each lane 10 µg genomic DNA were restricted
`with Xbal and hybridized with a probe comprising the entire coding region
`of erbB-2. HindIII restriction fragments of lambda DNA seived as mol. wt
`standards. (8) DNA dot-blot analysis. Genomic DNA (10 µg) digested with
`EcoRI was applied in serial 2-fold dilutions to nitrocellulose filters. Filters
`were hybridized either with erbB-2 {Figure I 8 , probe b) or mos, which
`served as a control for DNA amounts applied to replicate nitrocellulose
`filters. Gene copy numbers of erbB-2 relative to M41 3 indicate the minimal
`extent of gene amplification detected in DNA from mammary tumor cell
`lines.
`of MCF-7 , a mammary tumor cell line, that tlid not display
`overexpression of erbB-2 mRNA. We interpret these results to
`indicate that substantially more erbB-2 protein is found in both
`SK-BR-3 and Z R-75- 1 than in MCF-7 cells where the amount
`of protein escapes the sensitivity of the assay. Dilution ex(cid:173)
`periments suggest that SK-BR-3 contains between 5- and IO-fold
`more erbB-2 protein than does ZR-75-1 (data not shown).
`We also analyzed total cellular RN As of the same mammary
`tumor cell lines for evidence of EGFR receptor mRNA overex(cid:173)
`pression. Increased amounts of an apparently normal size EGFR
`607
`
`3 of 6
`
`Celltrion, Inc., Exhibit 1046
`
`

`

`M.H.Kraus tt al.
`
`.1, ..
`
`,
`
`Fig. S. Representative metaphase from the SK-BR-3 carcinoma cell line
`after in situ hybridization with an erbB-2 cDNA probe, autoradiography and
`G·banding. (A) A chromosome spread exhibiting silver grains on a
`distinctive, highly rcamnged chromosome (arrow). (B) The same spread
`after trypsin/EDT A treatment to produce G·bands. Detailed G·banding
`analysis did not indicate that the site of hybridization contains a
`homogeneously stained region (HSR).
`
`mRNA were observed in BT20 and MDA-MB468. These two
`cell lines have previously been shown to contain amplified EGFR
`genes. EGFR transcripts were elevated 16-fold in BT20 and
`32-fold in MDA-MB468 above the level seen in nonnal human
`fibroblasts as detennined by RNA dot-blot analysis (Table I).
`Genetic abnormalities associated with elevated erbB-2 expression
`To investigate alterations of the erbB-2 gene associated with
`mRNA overexpression, we examined Xbal-restricted high mol.
`wt DNA by Southern blot analysis using a probe comprising the
`entire coding sequence of erbB-2 (Figure IB, probe c). The nor(cid:173)
`mal restriction pattern of Xbal fragmentc; was dete:eted in all DNA
`samples analyzed indicating that gene rearrangements in prox(cid:173)
`imity of the erbB-2 coding region did not occur in these cell lines.
`When compared with nonnal human fibroblast DNA (Figure 4A,
`lane I) the erbB-2-specific Xbal restriction fragments appeared
`clearly amplified in the cell lines SK-BR-3, BT474 and MDA(cid:173)
`MB361 (Figure 4A, lanes 2-4). Similar results were obtained
`with restriction enzymes EcoRJ and Sad (data not shown).
`Quantitation of erbB-2 gene copy number was accomplished
`using DNA dot-blot analysis. These studies revealed a 4- to 8-fold
`
`608
`
`erbB-2 gene amplification in SK-BR-3 and BT474 relative to nor(cid:173)
`mal human DNA and a 2- to 4-fold erbB-2 gene amplification
`in MDA-MB361. In addition, a 2-fold erbB-2 gene amplifica(cid:173)
`tion was identified for the cell line MDA-MB453 by DNA dot(cid:173)
`blot analysis. Thus, gene amplification was associated with
`overexpression in the four tumor cell lines with the highest levels
`of erbB-2 mRNA (Table I). In contrast, gene amplification could
`not be detected by Southern blot analysis or DNA dot-blot
`analysis in the four tumor cell lines with erbB-2 transcript in(cid:173)
`creased to intennediate levels.
`To examine the nature of any chromosomal abnonnalities
`associated with overexpression we used in situ hybridization to
`localize the erbB-2 gene in two cell lines which either do or do
`not contain amplified gene copies. The erbB-2 gene has been
`mapped in nonnal human cells on chromosome 17ql 1.2-22
`(Schechter et al., 1985; Coussens et al., 1985; Fukushige et al.,
`1986). Mammary tumor cell line SK-BR-3 contains 4- to 8-fold
`gene amplification and 128-fold overexpression of erbB-2
`mRNA. In SK-BR-3, G-banding showed no copies of normal
`chromsome 17. In situ hybridization of the erbB-2 gene to these
`cells revealed accumulations of grains on two large abnonnal
`marker chromosomes derived from complex rearrangements in(cid:173)
`volving at least three chromosomes. An average of three grains
`was observed at each labelled site (Figure 5). These results in(cid:173)
`dicate that the amplification of the erbB-2 gene occurs in an ab(cid:173)
`nonnal chromosomal location and is not associated with either
`a homogeneously stained region or double minute chromosomes,
`abnormalities diagnostic for gene amplification (Biedler and
`Spengler, 1976; Levan et al., 1977). Mammary tumor cell line
`ZR-75-1 showed no evidence of gene amplification and an 8-fold
`overexpression of mRNA (Table I). Chromosome 17 was pre(cid:173)
`sent in one or two copies per cell. Analysis of 50 cells after in
`situ hybridization with a erbB-2 cDNA probe revealed the largest
`accumulation of grains on chromosome 17 with 85 % of these
`clustered on chromosome bands 17ql 1.2-21, the nonnal loca(cid:173)
`tion of the erbB-2 gene. This indicates that overexpression of
`the erbB-2 gene can occur in the absence of detectable structural
`abnormalities of chromosome 17.
`Mammary tumor cell lines overexpressing erbB-2 do not con(cid:173)
`tain readily detectable transforming genes
`In chemically induced rat neuroblastomas, a point mutation within
`the transmembranous domain activates the rat homologue of
`erbB-2, neu, to transforming activity readily detectable in the
`NIH/3T3 transfection assay (Bargmann et al., 1986b). Previous
`transfection analysis of21 mammary tumors and tumor cell lines
`did not reveal activation of erbB-2 as a transforming gene in
`human mammary neoplasia (Kraus et al., 1984). To investigate
`whether an activating lesion similar to the rat neu gene was
`associated with the overexpression of erbB-2 in human mam(cid:173)
`mary tumor cell lines, we transfected genomic DNA of these
`cell lines into mouse Nlli/31'3 cells. Under conditions where high
`mol. wt DNA from the cell line T24 which is known to contain
`an activated H -ra.~ oncogene induced 4-8 foci/plate, genomic
`DNA from eight mammary tumor cell lines which overexpress
`erbB-2 did not induce detectable morphological transfonnation
`(Table II).
`
`Disc~ion
`Analysis of 16 human mammary tumor cell lines for the EGF
`receptor and the related erbB-2 gene revealed frequently increased
`transcript levels of either member of this family of growth fac(cid:173)
`tor receptor genes. In BT20 and MDA-MB468 overexpression
`
`4 of 6
`
`Celltrion, Inc., Exhibit 1046
`
`

`

`Table D. DNA transfeclion of human mammary rumor cell lines
`
`Source of genomic DNA
`
`FFU/plate•
`
`T24 prep I
`T24 prep 2
`T24 prep 3
`SK-BR-3
`BT474
`MDA-MB361
`MDA-MB453
`ZR-75-1
`ZR-75-30
`BT483
`MDA-MBl75
`
`32/4
`19/4
`16/4
`0112
`0112
`012
`0/4
`0/8
`0/4
`014
`0/8
`
`"FFU/plate = focus-forming units/number of 1ransfected plates. 30 µg high
`mol. wt DNA were coprecipitated with calcium phosphate and transfected
`onto NDi/3T3 fibroblasts as previously described (Wigler et al., 1977).
`Genomic T24 DNA served as positive control for each assay.
`
`of normal size EGF receptor gene transcripts is associated with
`gene amplification (King et al., I 985b; Filmus er al., 1985). In(cid:173)
`creased transcript levels of erbB-2 were detected in the presence
`and absence of gene amplification, indicating that erbB-2 over(cid:173)
`expression in human mammary tumor cell lines can be caused
`by different molecular mechanisms. The absence of aberrantly
`sized erbB-2 mRNA in Northern blot analysis suggests that a
`nonnal size mRNA is overexpressed in mammary tumor cell lines
`rather than a rearranged form. Moreover, the fact that genomic
`DNA from these cell lines lacked the ability to transform
`NIH/3T3 cells by transfection indicates that point mutations
`similar to those that can activate the rat neu gene did not occur.
`These observations provide evidence that a structurally normal
`coding sequence of erbB-2 is overexpressed as mRNA in human
`mammary tumor cell lines. Protein analysis of representative
`samples with erbB-2 overexpression suggests that elevated erbB-2
`transcript levels are translated into erbB-2 proteins.
`Several lines of evidence link the overexpression of proto(cid:173)
`oncogenes to the neoplastic process. The increased transcription
`of nonnal coding sequences of either the human c-sis/PDGF gene
`or the H-ras gene using a viral long terminal repeat promoter
`induces transformation of NIH/3T3 cells in culture (Chang er
`al., 1982; Gazit er al., 1984). Moreover, in human tumors myc
`or N-myc amplification correlates with increased malignancy
`(Kohl er al., 1983; Schwab er al., 1983; Nau er al., 1984). Our
`results link erbB-2 overexpression to the neoplastic growth of
`mammary tumor cells.
`Gene amplification of multidrug resistance genes is observed
`in cells selected for the ability to grow in media containing cer(cid:173)
`tian metabolic inhibitors (AJt er al., 1978). There is evidence
`that overexpression of these genes can precede gene amplifica(cid:173)
`tion in the development of multidrug resistance (Shen er al. ,
`1986). Our observation of elevated erbB-2 transcript levels in
`the presence and absence of gene amplification may reflect a
`similar pathway. Overexpression of erbB-2 may confer an in(cid:173)
`itial selective growth advantage to the tumor cell and subsequent
`gene amplification cause a further step where the selective growth
`advantage is enhanced and stabilized. erbB-2 overexpression is
`consistently higher in those samples with gene amplification when
`compared with cell lines lacking gene amplification. Interestingly,
`the amount of overexpression per gene copy is approximately
`constant in the cell lines that overexpress erbB-2 (Table I). This
`suggests that deregulated erbB-2 expression due to different
`molecular mechanisms in mammary tumor cell lines may be part
`
`Overexp~on of the erbB-2 gene in mammary tumor cells
`
`of a multistep process which confers selective growth advantage
`to a mammary tumor cell.
`In all cell lines examined we detected no abnormalities of
`erbB-2 gene structure by Southern blot hybridization. Moreover,
`in ZR-75-1, in which overexpression occurs without gene
`amplification, the erbB-2 gene was located at its normal site on
`chromosome 17. These results indicate that mechanisms of
`deregulation are unlikely to involve the type of rearrangements
`responsible for activation of the myc gene in Burkitt's lymphoma
`(Taub er al., 1982; Dalla-Favera er al., 1983). Deregulation of
`erbB-2 gene expression may therefore involve subtle changes in
`cis-acting control sequences, changes involving transacting
`regulatory elements, or changes which enhance mRNA stab~ity.
`Abnormalities of erbB-2 and EGFR genes are not restncted
`to mammary tumor cells in culture, as we and others have iden(cid:173)
`tified erbB-2 or EGFR gene amplification in several samples of
`mammary tumor tissue (King er al. , l 985a; Yokota et al. , 1986,
`and unpublished observation). The precise action of growth fac(cid:173)
`tor receptor gene overexpression in the neoplastic process of
`mammary tumor cells has yet to be established. However, since
`tumorigenicity of mammary tumor cells can be enhanced by
`steroid hormones or polypeptide growth factors (Kasid er al. ,
`1985; Dickson et al., 1986), it is tempting to hypothesize that
`the overexpression of polypeptide growth factor receptors in(cid:173)
`creases tumorigenicity by stimulation of the same or similar
`growth signalling pathways. Forty percent of mammary tumor
`cell lines analyzed did not exhibit overexpression of erbB-2 or
`EGFR. Heterogeneity of steroid receptor expression is of con(cid:173)
`siderable therapeutic and prognostic value in human mammary
`neoplasia (McClelland er al., 1986; DeSombre er al., 1986). Our
`results strongly suggest an additional level of heterogeneity defin(cid:173)
`ed by overexpression of the erbB-2 or EGFR gene.
`In the cell line SK-BR-3, where we identified an amplified and
`overexpressed erbB-2 gene, a myc gene amplification with over(cid:173)
`expression has been previously reported (Kozbor and Croce,
`1984). The myc gene has been shown to cooperate with a ras
`gene in the transformation of primary fibroblasts (Land er al. ,
`1983). It will be of interest to determine whether overexpres(cid:173)
`sion of erbB-2 and myc can complement each other in promoting
`the growth of mammary tumor cells. In addition, systematic
`analysis of mammary tumors will determine whether overexpres(cid:173)
`sion of erbB-2 or the EGFR gene can be associated with a par(cid:173)
`ticular clinical manifestation of mammary carcinoma.
`
`Materials and methods
`
`Tumor cell lines
`Human mammary rumor cell lines were obtained from ATCC (American Type
`Culture Collection) and cultured according to the supplier's recommendation.
`
`RNA blorting
`Total cellular RNAs were isolated by CsCl-gradient centrifugation (Chirgwin et
`al., 1979). For Northern blot analysis 10 µg tOOll RNA were denarured and electro(cid:173)
`phoresed in I% formaldehyde gels (Lehrach et al., 1977). Following mild alkali
`degradation (50 mM NaOH at 24°C for 30 min) RNA wa~ transfen-ecl to
`nitrocellulose filters using I M ammonium acetate as a convectant. RNA dot(cid:173)
`blot analysis was conducted by applying serial 2-fold dilutions of total RNA in
`I M ammonium acetate to replicate nitrocellulose filters in a dot-blot manifold.
`
`DNA blotting
`For Southern blot analysis DNA samples (10 µg} were restricted with Xbal and
`subjected to electrophoresis in 0.8% agarosc gels. DNAs were transferred to ni~
`cellulose filters by the method of Southern (Southern, 1975). For dot-blot analysis
`DNAs were cleaved with EcoRI, denatured with 0.1 M NaOH and nwtraliz.cd
`with I M ammonium acetate. Serial 2-fold dilutions of each sample were ap(cid:173)
`plied to replicate nitrocellulose filters using a dot-blot manifold.
`
`609
`
`5 of 6
`
`Celltrion, Inc., Exhibit 1046
`
`

`

`Kohl.N.E., Kunda,N., Schreck,R.R., 8runs,G .• Latt,S.A., Gilbert,G. and
`Alt,F.W. (1983) Cell, 35. 349-367.
`Kozbor,O. and Croce,C.M. (1984) Cancer Res .• 44. 438-441.
`Kraus,M.H., Yuasa,Y. and Aaronson.S.A. (1984) Proc. Natl. Acad. Sci. USA.
`81, 5384-5388.
`Land,H., Parada,L.F. and Weinberg,R.A. (1983) Nature, 304, 596- 602.
`Lehrach,H., Oiamond,K., Wozney,J.M. and Boedtker,H. (1977) Biochemistry,
`16, 4743-4751.
`Levan,A .. Levan,G. and Mitelman,F. (1977) Hereditas, 86. 15-29.
`Libermann,T.A., Nusbaum,H.R., Razon,N .. Kris,R., Lax,J., Soreg,H., Whittle,
`N .. Waterfield,M.D., Ullrich,A. and Schlessinger,J. (1985) Na.lure, 313,
`144-147.
`Lowry,O.H., Rosebrough,N.J., Farr,A.L. and Randall,R.J. (1951) J. Biol.
`Chem., 193, 265 - 275.
`McClelland,R.A., Bergcr,U., Miller,L.S .. Powles,T.J., Jensen,E.V. and
`Coombes,R.C. (1986) Cancer Res. (Suppl.), 46, 424ls-4243s.
`Nau,M.M., Camey,D.N., Battey,J., Johnson,B .. Little,C .. Gaz.dar,A. and Min(cid:173)
`na,J.O. (1984) Curr. Top. Microbiol. lmmunol .• 113, 172-177.
`Okayama,H. and Berg,P. (1983) Mo/. Cell. Biol., 3, 280-289.
`Popescu,N.C., Amsbaugh,S.C., DiPaolo,J.A., Tronick,S.R .. Aaronson,S.A. and
`Swan,O.C. (1985a) Somat. Cell Mo/. Genet., 11, 149 - 155.
`Popescu,N.C., Amsbaugh,S.C., Swan,0.C. and OiPaolo,J.A. (1985b) Cytogenet.
`Cell Genet., 39. 73-74.
`Schechter,A.L., Hung,M.C., Vaidyanathan,L., Weinberg,R.A., Yang-Feng,T.L.,
`Francke,U., Ullrich,A. and Coussens,L. (1985) Science, 229, 976- 978.
`Schwab,M., Alitalo,V., Klempnauer,K.H., Varmus,H.E., 8ishop,J.M.,
`Gilbert,F., Brodeur,G., Goldstein.M. and Trent,J. (1983) Nature, 305,
`245- 248.
`Semba,K., Kamata,N., Toyoshima,K. and Yamamoto,T. (1985) Proc. Na1/. Acad.
`Sci. USA, 82, 6497- 6501.
`Shen,O.W., Fojo,A., Chin,J.E., Roninson,1.8 .. Richen,N .. Pastan,I. and Got(cid:173)
`tesman,M.M. (1986) Science, 232, 643- 645.
`Sherr,C.J., Rettenmier,C.W., Sacca,R., Roussel,M.F., Look,A.T. and
`Stanley,E.R. (1985) Cell. 41, 665-676.
`Shih,C., Padhy,L., Murray,M. and Weinberg,R.A. (1981) Nature, 290,
`261-264.
`Southem,E.M. (1975) J. Mo/. Biol., 98, 503 - 517.
`Stem,O.F., Heffeman,P.A. and Weinberg,R.A. (1986) Mo/. Cell. Biol. , 6,
`1729-1740.
`Taub,R., Kirsch,!., Morton,C., Lenoir,G., Swan,O .. Tronick,S., Aaronson,S.
`and Leder,P. (1982) Proc. Natl. Acad. Sci. USA, 97, 7837 - 7841.
`Walter,P., Green,S., Greene,G., Krust,A., Bornert,J.M., Jeltsch,J.M., Staub.A.,
`Je.nsen,E., Scrace,G., Waterfield,M. and Chambon.P. (1985) Proc. Na1/. Acad.
`Sci. USA, 82, 7889- 7893.
`Waterfield,M.O .. Scrace,G.T .. Whittle,N., Stroobant,P., Jonson.A., Wasteson,
`A., Westermark,8., Heldin,C.H .. Huang,J.S. and Deuel.T.F. (1983) Nature,
`304, 35- 39.
`Wigler,M., Silverstein,S., Lee.L.S., Pellicer,A., Cheng,Y.C. and Axcl,R. (1977)
`Cell, 11, 223 - 232.
`Yamamoto,T .. l.kawa,S .. Akiyama,T., Semba,K., Nomura,N., Miyajima,N.,
`Saito,T. and Toyoshima,K. (1986a) Na1ure, 319, 230-234.
`Yamamoto,T .. Kamata,N., Kawano,H., Shimizu.S .. Kuroki,T., Toyoshima,K.,
`Rikimaru,K., Nomura,N .. lshizaki,R., Pastan,J., Gamon,S. and Shimizu,N.
`(1986b) Cancer Res .• 46, 414-416.
`YokotaJ .. Yamamoto.T., Toyoshima,K., Terada,M .. Sugimura,T .. Battifora,H.
`and Cline,M.J. (1986) lancet, (i) (8484), 765-767.
`
`Received on January 5, 1987
`
`Note added in proof
`
`After submission of this manuscript, a srudy by Slamon,0. et al., ((1987) Science,
`235, 177 - 182] indicated a correlation of erbB-2 gene amplification and reduced
`disease-free survival in breast cancer patients.
`
`M.H.Kraus el al.
`
`Hybridi(.Qtion
`Hybridization was conducted at 42°C in 750 mM NaCl, 75 mM Na citrate and
`50% formamide. The filters were washed under stringency conditions of 15 mM
`NaCl and 1.5 mM Na citrate at 50°C.
`lmmunoblotting
`One confluent 100 mm plate of each cell line was lysed in I % Triton, 0 .1 % SOS.
`0 .5% deoxycholate, 10 mM sodium phosphate pH 7.4, 0.1 M sodium chloride,
`I mM phenylrnethyl sulfonyl fluoride, and centrifuged at 12 000 g for 10 min
`at 4 °C. The supernatant was tested for protein concentration using the method
`of Lowry (Lowry et al., 1951) and adjusted to I% SOS, 50 mM Tris-HCI pH
`6 .8, 0.1 % (3 mercaptoethanol, 5% glycerol and 0.01 % bromophenol blue. After
`heat treatment (100°C for 5 min), 40 µg of each sample was subjected to poly(cid:173)
`acrylamide gel (7 % ) electrophoresis and transferred to nitrocellulose. The nitro(cid:173)
`cellulose was treated for 1 h in Blotto solution (2% nonfat dry milk, 1 % Triton,
`50 mM Tris- HCI pH 7.4, JO mM EOTA). The lgG fraction of an antipeptide
`antibody directed against amino acids 866-880 of the erbB-2 protein was con(cid:173)
`ducted in Blotto for 2 h. Blots were washed three times with Blotto solution for
`JO min each. Reaction with 2 x lOS c.p.m./ml of 1125 protein A was conducted
`for 20 min at room temperarure. The blots were then washed three times for
`10 min with Blotto solution and 20 times with water. Detection was accomplish(cid:173)
`ed by autoradiography at - 70°C.
`In situ hybridiwtion
`Exponentially growing culrures of ZR-75-1 and SK-BR-3 were exposed to col(cid:173)
`cemid (0.05 µg/ml) and ethidium bromide (7 .5 µglml) for 4 and 2 h, respective(cid:173)
`ly, before harvesting for chromosome preparation. In situ hybridization was canied
`out under stringent conditions as previously described (Harper and Saunders, 1981;
`Popescu et al., 1985a) using 3H-labelled erbB-2 cDNA as probe. The hybridiz(cid:173)
`ed slides were coated with nuclear track emulsion NTB-2, diluted 1: 1 with H20
`and sto

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket